<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512821</url>
  </required_header>
  <id_info>
    <org_study_id>2016-4053</org_study_id>
    <nct_id>NCT03512821</nct_id>
  </id_info>
  <brief_title>A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fed Conditions</brief_title>
  <official_title>A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      single-dose, comparative bioavailability study of two formulations of ursodiol 500mg tablets
      under fed conditions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-dose, comparative bioavailability study of two formulations of ursodiol 500mg
      tablets under fed conditions: open label, single-dose, randomized, two-period, two-treatment,
      two-sequence, crossover, comparative bioavailability study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0-72hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>0-72hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ursodiol 500mg tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ursodiol 500mg tablets followed by Urso Forte 500mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urso Forte 500mg tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Urso forte 500mg tablets followed by Ursodiol 500mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodiol 500 MG</intervention_name>
    <description>Ursodiol 500mg tablets followed by Urso Forte 500mg tablets</description>
    <arm_group_label>Ursodiol 500mg tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urso Forte 500Mg Tablet</intervention_name>
    <description>Urso forte 500mg tablets followed by Ursodiol 500mg tablets</description>
    <arm_group_label>Urso Forte 500mg tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, non-smoking, male and female subjects, 18 years of age or older

          -  BMI ≥ 19.0 and ≤ 30.0 kg/m2.

          -  Females who participate in this study will be of chilbearing or nonchildbearing
             potential

        Exclusion Criteria:

        • Known history or presence of clinically significant neurologic, hematologic, endocrine,
        oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or
        any other condition which, in the opinion of the investigator, would jeopardized the safety
        of the subject or impact the validity of the study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharma medica research Inc.</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>6100</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

